Evidence map›Paper›PMID 39706265›Full record

ArticleThe Journal of biological chemistry2025

The physicochemical properties of lipopolysaccharide chemotypes regulate activation of the contact pathway of blood coagulation.

André L Lira, Berk Taskin, Cristina Puy, Ravi S Keshari, Robert Silasi, Jiaqing Pang, Joseph E Aslan, Joseph J Shatzel, Christina U Lorentz, Erik I Tucker and 4 more

Abstract read
In one paragraph

Article in The Journal of biological chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

André L LiraDepartment of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon, USA. Electronic address: dasilva@ohsu.edu.
Berk TaskinDepartment of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon, USA.
Cristina PuyDepartment of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon, USA.
Ravi S KeshariCardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA.
Robert SilasiCardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA.
Jiaqing PangDepartment of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon, USA.
Joseph E AslanDepartment of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon, USA; Knight Cardiovascular Institute, Oregon Health & Science University, Portland, Oregon, USA.
Joseph J ShatzelDepartment of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon, USA; Division of Hematology and Medical Oncology, School of Medicine, Oregon Health & Science University, Portland, Oregon, USA.
Christina U LorentzDepartment of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon, USA; Aronora, Inc, Portland, Oregon, USA.
Erik I TuckerDepartment of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon, USA; Aronora, Inc, Portland, Oregon, USA.
Alvin H SchmaierDivision of Hematology and Oncology, Department of Medicine, Case Western Reserve University and University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
David GailaniDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Florea LupuCardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA.
Owen J T McCartyDepartment of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon, USA; Knight Cardiovascular Institute, Oregon Health & Science University, Portland, Oregon, USA.

Funding

Characterization of Coagulation Factor-platelet Interactions: Role of FXIR01HL101972 · NHLBI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Owen J McCarty · 2010 to 2026
$8.5M
Biochemistry and Pathophysiology of Factor XI and Contact ActivationR35HL140025 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI GAILANI, DAVID · 2018 to 2024
$5.5M
Contact Activation and InfectionR01AI157037 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI LUPU, FLOREA, MCCARTY, OWEN J · 2020 to 2024
$3.3M
Tyrosine Kinases and ThrombosisR01HL157405 · NHLBI · CASE WESTERN RESERVE UNIVERSITY · PI SCHMAIER, ALVIN H · 2022 to 2025
$1.9M
Evaluating the Safety and Efficacy of Targeting the Contact Pathway to Prevent Device Associated Thrombosis.R01HL151367 · NHLBI · OREGON HEALTH & SCIENCE UNIVERSITY · PI SHATZEL, JOSEPH JAMES · 2020 to 2024
$1.5M
NHLBI NIH HHS R01 HL101972NHLBI NIH HHS R01 HL144133NHLBI NIH HHS R01 HL151367NHLBI NIH HHS R01 HL157405NHLBI NIH HHS R35 HL140025NIAID NIH HHS R01 AI157037
6 · The paper itself

Abstract

Lipopolysaccharide (LPS) is the primary pathogenic factor in Gram-negative sepsis. While the presence of LPS in the bloodstream during infection is associated with disseminated intravascular coagulation, the mechanistic link between LPS and blood coagulation activation remains ill-defined. The contact pathway of coagulation-a series of biochemical reactions that initiates blood clotting when plasma factors XII (FXII) and XI (FXI), prekallikrein (PK), and high molecular weight kininogen interact with anionic surfaces-has been shown to be activated in Gram-negative septic patients. In this study, using an in vivo baboon model of Gram-negative Escherichia coli sepsis, we observed activation of the contact pathway including FXII, FXI, and PK. We examined whether E.coli LPS molecules could bind and activate contact pathway members by quantifying the interaction and activation of either FXII, FXI, or PK with each of the three chemotypes of LPS: O111:B4, O26:B6, or Rd2. The LPS chemotypes exhibited distinct physicochemical properties as aggregates and formed complexes with FXII, FXI, and PK. The LPS chemotype O26:B6 uniquely promoted the autoactivation of FXII to FXIIa and, in complex with FXIIa, promoted the cleavage of FXI and PK to generate FXIa and plasma kallikrein, respectively. Furthermore, in complex with the active forms of FXI or PK, LPS chemotypes were able to regulate the catalytic activity of FXIa and plasma kallikrein, respectively, despite the inability to promote the autoactivation of either zymogen. These data suggest that the procoagulant phenotype of E.coli is influenced by bacterial strain and the physicochemical properties of the LPS chemotypes.

Indexed as

Blood CoagulationEscherichia coliEscherichia coli InfectionsLipopolysaccharidesAnimalsFactor XIIHumansPapioPrekallikreinSepsisFactor XIILipopolysaccharidesPrekallikreincoagulationcontact pathwayfactor XIIlipopolysaccharidessepsis

Identifiers

PMID39706265
PMCPMC11773025

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.